by Dana T. Lounder, Qiong Bin, Cristina de Min, and Michael B. Jordan

Slides:

Advertisements

Similar presentations

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

Advertisements

Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease by Monica L. Hulbert,

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Cytotoxic therapy for severe swine flu A/H1N1

Case Western Reserve University and University Hospitals of Cleveland

18th Meeting of the European Association for Hematopathology

Cell type specific infection of Epstein–Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection Yoshihito.

Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses by Alain H. Rook, Gary S. Wood, Elisa K. Yoo,

by Rahul Matnani, and Karthik A. Ganapathi

EBV DNA: a Hodgkin lymphoma biomarker?

by Christopher Dittus, and Dana Semmel

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma by Jean-Louis H. Kerkhoffs,

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load by Steven G. Deeks, Christina.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

A novel immunoregulatory role for NK-cell cytotoxicity in protection from HLH-like immunopathology in mice by Fernando E. Sepulveda, Sophia Maschalidi,

by Elham Kamangar, and Weiqiang Zhao

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

Effect of a Recombinant Dimeric Tumor Necrosis Factor Receptor on Inflammatory Responses to Intravenous Endotoxin in Normal Humans by Tom van der Poll,

by Alexander Röth, Andreas Hüttmann, Russell P

Intima-media thickness of the common femoral artery as a marker of leg ulceration in sickle cell disease patients by Oluwagbemiga O. Ayoola, Rahman A.

by Simon F. De Meyer, Alexander S. Savchenko, Michael S

Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients.

Differentiation, phenotype, and function of interleukin-17–producing human Vγ9Vδ2 T cells by Nadia Caccamo, Carmela La Mendola, Valentina Orlando, Serena.

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

M. Jensenius, P. -E. Fournier, K. B. Helium, L. Wesslén, G. Caruso, T

Hyperviscosity syndrome

Human NK cells can control CMV infection in the absence of T cells

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

HU for acute treatment of sickle VOC?

Gastrointestinal Toxicity, Systemic Inflammation, and Liver Biochemistry in Allogeneic Hematopoietic Stem Cell Transplantation Karina Jordan, Peter Pontoppidan,

Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo by Rukhsana.

M. Jensenius, P. -E. Fournier, K. B. Helium, L. Wesslén, G. Caruso, T

بسم الله الرحمن الرحیم.

Line graph showing change in size over time relative to baseline CT

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial by Ersi Voskaridou,

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)‏ by Ahmed A. Daak, Carlton D. Dampier, Beng.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions by Priyanka Pandey, Waseem Q. Anani,

Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD by Sarah A. Wall, Qiuhong Zhao, Martha.

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD by Gérard Socié, Noel Milpied, Ibrahim.

Evidence for human immunodeficiency virus and Cryptococcus neoformans interactions in the pro-inflammatory and anti-inflammatory responses in blood during.

by Geling Li, Emily Waite, and Julie Wolfson

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Significant gynecological bleeding in women with low von Willebrand factor levels by Michelle Lavin, Sonia Aguila, Niall Dalton, Margaret Nolan, Mary Byrne,

Volume 2(Supplement 1):1-3

by Eric J. Vick, Kruti Patel, Philippe Prouet, and Mike G. Martin

Volume 14, Issue 1, Pages (July 2006)

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease by Jennifer S. Whangbo, Haesook.

by Nicholas J. Laping, Michael P. DeMartino, Joshua E

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

Plasma biomarker concentrations between study groups.

by Michael R. DeBaun, and Ellen Wright Clayton

Ontogeny of platelet function

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults by Paul La Rosée, AnnaCarin Horne, Melissa Hines, Tatiana von Bahr Greenwood,

Monitoring the induction of pro-inflammatory mediators and toll-like receptors (TLRs) following inhalation of AZD8848. Monitoring the induction of pro-inflammatory.

Figure 2 Evolution of blood cell counts during interleukin (IL)–7 therapy Evolution of blood cell counts during interleukin (IL)–7 therapy The leukocyte.

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Bv+Bs regimen schedule.

Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient by Jian-Ping Zhang, Rui Zhang, Shih-Ting Tsao,

by Sumita Ratnasingam, Patricia A. Walker, Huy Tran, Zane S

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

How I treat hemophagocytic lymphohistiocytosis

Central nervous system–restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation by Hojun Li, Leslie A. Benson,

How I treat heparin-induced thrombocytopenia and thrombosis

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI by Naranie Shanmuganathan, Susan.

Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non–transferrin-bound iron by Eldad.

Presentation transcript:

by Dana T. Lounder, Qiong Bin, Cristina de Min, and Michael B. Jordan Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections by Dana T. Lounder, Qiong Bin, Cristina de Min, and Michael B. Jordan BloodAdv Volume 3(1):47-50 January 8, 2019 © 2019 by The American Society of Hematology

Dana T. Lounder et al. Blood Adv 2019;3:47-50 © 2019 by The American Society of Hematology

HLH disease features and viremias after treatment with emapalumab. HLH disease features and viremias after treatment with emapalumab. (A-B) Absolute neutrophil and platelet counts, both heavily supported by transfusion until about day 21. (C-D) Fibrinogen (supported by fresh-frozen plasma transfusion until day 21) and D-dimer levels. (E-F) Alanine aminotransferase (ALT) and direct bilirubin levels. (G-H) The inflammatory markers ferritin and soluble interleukin-2 receptor (sIL2r [sCD25]). Reported ferritin values are limited to 40 000 μg/L by the clinical laboratory. Ferritin values decreased to <500 μg/L by day 180. (I-J) Blood levels of EBV and CMV. Arrows on the x-axis of each graph indicate the start of emapalumab treatment, and initial and final values for each marker are shown. Dana T. Lounder et al. Blood Adv 2019;3:47-50 © 2019 by The American Society of Hematology

IFN-γ–associated chemokines after treatment with emapalumab. IFN-γ–associated chemokines after treatment with emapalumab. The levels of CXCL9 (A) and CXCL10 (B), 2 chemokines induced by IFN-γ, after initiation of therapy with emapalumab. Baseline and final levels for each biomarker are indicated. Dana T. Lounder et al. Blood Adv 2019;3:47-50 © 2019 by The American Society of Hematology